Highlights
- Market Cap
- $108.84M
- Enterprise Value
- $102.90M
- EPS (TTM)
- -$1.89
- EBITDA (TTM)
- -$100.09M
- Year Range
- $0.40 - $2.66
- Target Price
- $4.00
- ROA (TTM)
- -172.23%
- ROE (TTM)
- -391.42%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in ALX Oncology Holdings Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
ALX Oncology Holdings Inc. (ALXO) has returned 77.43% so far this year and 221.83% over the past 12 months.
ALX Oncology Holdings Inc.
- 1D
- 4.97%
- 1M
- -4.98%
- YTD
- 77.43%
- 6M
- 9.56%
- 1Y
- 221.83%
- 3Y*
- -23.73%
- 5Y*
- -51.43%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Jul 17, 2020, ALXO's average daily return is 0.00%, while the average monthly return is +0.60%. At this rate, your investment would double in approximately 9.7 years.
Historically, 45% of months were positive and 55% were negative. The best month was Aug 2025 with a return of +106.2%, while the worst month was Aug 2024 at -51.7%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 6 months.
On a daily basis, ALXO closed higher 48% of trading days. The best single day was Oct 3, 2023 with a return of +56.1%, while the worst single day was Aug 1, 2024 at -41.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 53.98% | 21.26% | -4.98% | 77.43% | |||||||||
| 2025 | -12.57% | -24.66% | -43.36% | -13.32% | -10.09% | -14.50% | 36.71% | 106.17% | 56.41% | -15.85% | -11.04% | -17.52% | -32.34% |
| 2024 | -3.22% | 1.80% | -23.99% | 52.65% | -37.54% | -43.27% | -20.40% | -51.67% | -21.55% | -21.43% | 3.50% | 12.84% | -88.78% |
| 2023 | -17.48% | -28.82% | -31.72% | 31.42% | 12.29% | 12.59% | -18.64% | -30.28% | 12.68% | 50.00% | 8.89% | 89.92% | 32.12% |
| 2022 | -25.55% | 13.25% | -6.73% | -24.38% | -39.98% | 5.48% | 19.65% | 34.30% | -26.38% | 26.85% | -8.57% | 1.53% | -47.56% |
| 2021 | -8.06% | 1.31% | -8.16% | -15.03% | -9.74% | -3.32% | 7.10% | 19.54% | 5.51% | -24.13% | -42.61% | -33.18% | -75.07% |
Benchmark Metrics
ALX Oncology Holdings Inc. has an annualized alpha of -15.82%, beta of 1.28, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since July 20, 2020.
- This stock participated in 165.67% of S&P 500 Index downside but only -34.00% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -15.82%
- Beta
- 1.28
- R²
- 0.05
- Upside Capture
- -34.00%
- Downside Capture
- 165.67%
Return for Risk
Risk / Return Rank
ALXO ranks 87 for risk / return — in the top 87% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ALX Oncology Holdings Inc. (ALXO) and compare them to a chosen benchmark (S&P 500 Index).
| ALXO | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.89 | 0.90 | +1.00 |
Sortino ratioReturn per unit of downside risk | 2.86 | 1.39 | +1.47 |
Omega ratioGain probability vs. loss probability | 1.31 | 1.21 | +0.10 |
Calmar ratioReturn relative to maximum drawdown | 4.08 | 1.40 | +2.68 |
Martin ratioReturn relative to average drawdown | 8.57 | 6.61 | +1.97 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore ALXO risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the ALX Oncology Holdings Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ALX Oncology Holdings Inc. was 99.64%, occurring on Jun 27, 2025. The portfolio has not yet recovered.
The current ALX Oncology Holdings Inc. drawdown is 98.21%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.64% | Dec 11, 2020 | 1140 | Jun 27, 2025 | — | — | — |
| -27.58% | Aug 18, 2020 | 32 | Oct 1, 2020 | 28 | Nov 10, 2020 | 60 |
| -17.51% | Nov 24, 2020 | 2 | Nov 25, 2020 | 10 | Dec 10, 2020 | 12 |
| -7.17% | Aug 10, 2020 | 2 | Aug 11, 2020 | 3 | Aug 14, 2020 | 5 |
| -4.58% | Jul 22, 2020 | 1 | Jul 22, 2020 | 4 | Jul 28, 2020 | 5 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ALX Oncology Holdings Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ALX Oncology Holdings Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ALXO in comparison with other companies in the Biotechnology industry. Currently, ALXO has a P/B value of 4.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |